🇺🇸 Decitabine and cedazuridine in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 3
Most-reported reactions
- Angle Closure Glaucoma — 1 report (33.33%)
- Choroidal Effusion — 1 report (33.33%)
- Condition Aggravated — 1 report (33.33%)
Other Oncology approved in United States
Frequently asked questions
Is Decitabine and cedazuridine approved in United States?
Decitabine and cedazuridine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Decitabine and cedazuridine in United States?
Race Oncology Ltd is the originator. The local marketing authorisation holder may differ — check the official source linked above.